Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR/Cas9-double nickase reveals potential safety concerns-Reference-Cited by-同舟云学术

Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR/Cas9-double nickase reveals potential safety concerns

Published:2018-12 Issue:4 Volume:2 Page:046103
ISSN:2473-2877
Container-title:APL Bioengineering
language:en
Short-container-title:APL Bioengineering

Author:

Alateeq Suad¹²,Ovchinnikov Dmitry¹,Tracey Timothy¹,Whitworth Deanne³,Al-Rubaish Abdullah⁴,Al-Ali Amein²,Wolvetang Ernst¹^ORCID

Affiliation:

1. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia

2. Department of Biochemistry, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31451, Kingdom of Saudi Arabia

3. School of Veterinary Science, The University of Queensland, Gatton, QLD 4343, Australia

4. Department of Internal Medicine, College of Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam 31451, Kingdom of Saudi Arabia

Publisher

AIP Publishing

Subject

Biomedical Engineering,Biomaterials,Biophysics,Bioengineering

Link

http://aip.scitation.org/doi/pdf/10.1063/1.5048625

Reference56 articles.

1. Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery

2. Highly efficient Cas9-mediated transcriptional programming

3. Comparison of Cas9 activators in multiple species

4. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system

5. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR-Cas9 Direct Fusions for Improved Genome Editing via Enhanced Homologous Recombination;International Journal of Molecular Sciences;2023-09-28

2. CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia;Thalassemia Reports;2023-02-06

3. CRISPR/Cas9, a promising approach for the treatment of β-thalassemia: a systematic review;Molecular Genetics and Genomics;2022-11-20

4. Robust genome and RNA editing via CRISPR nucleases in PiggyBac systems;Bioactive Materials;2022-08

5. Homozygous might be hemizygous: CRISPR/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls;Stem Cell Reports;2022-04